1.World Health Organization (WHO). Human papillomavirus vaccines: WHO position paper, May 2017. Wkly Epidemiol Rec. 2017;92(19):241–268.
2.ACOG. Committee Opinion No. 704: Human Papillomavirus Vaccination. Obstet Gynecol. 2017;129(6):e173-e178.
3.Markowitz LE, Dunne EF, Saraiya M, et al. Human Papillomavirus Vaccination Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2014;63(5):1-36.
4.Canadian Immunization Guide: Part 4 - Active Vaccines. Human Papillomavirus Vaccine. May 2017. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-9-human-papillomavirus-vaccine.html#p4c8a5_d.
5.中华预防医学会妇女保健分会. 子宫颈癌综合防控指南. 北京：人民卫生出版社. 2017
6.Wei L, et al. Efficacy of quadrivalent human papillomavirus vaccine against
persistent infection and genital disease in Chinese women: A randomized, placebo-controlled trial
with 78-month follow-up[J]. Vaccine, 2018.
7.Castellsague X, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. British Journal of Cancer. 2011,105;28–37.
8.Arana J E, et al. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009–2015[J]. Vaccine, 2018, 36(13): 1781-1788.
9.CDC.https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2018-02/HPV-02-Arana-508.pdf.
10.WHO https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2018-02/HPV-03-Donahue-508.pdf.
11.双价人乳头瘤病毒吸附疫苗说明书.
12.四价人乳头瘤病毒疫苗（酿酒酵母）说明书.
13.九价人乳头瘤病毒疫苗（酿酒酵母）说明书.
